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Abstract
Background: Numerous epidemiological studies demonstrate that genetic background modifies the onset and the
progression of Alzheimer’s disease and related neurodegenerative disorders. The efficacious influence of genetic
background on the disease pathway of amyloid beta has been meticulously described in rodent models. Since the
impact of genetic modifiers on the neurodegenerative and neuroinflammatory cascade induced by misfolded tau
protein is yet to be elucidated, we have addressed the issue by using transgenic lines expressing the same human
truncated tau protein in either spontaneously hypertensive rat (SHR) or Wistar-Kyoto (WKY) genetic background.
Methods: Brains of WKY and SHR transgenic rats in the terminal stage of phenotype and their age-matched non-
transgenic littermates were examined by means of immunohistochemistry and unbiased stereology. Basic measures
of tau-induced neurodegeneration (load of neurofibrillary tangles) and neuroinflammation (number of Iba1-positive
microglia, their activated morphology, and numbers of microglia immunoreactive for MHCII and astrocytes
immunoreactive for GFAP) were quantified with an optical fractionator in brain areas affected by neurofibrillary
pathology (pons, medulla oblongata). The stereological data were evaluated using two-way ANOVA and Student’s
t-test.
Results: Tau neurodegeneration (neurofibrillary tangles (NFTs), axonopathy) and neuroinflammation (microgliosis,
astrocytosis) appeared in both WKY and SHR transgenic rats. Although identical levels of transgene expression in
both lines were present, terminally-staged WKY transgenic rats displayed significantly lower final NFT loads than
their SHR transgenic counterparts. Interestingly, microglial responses showed a striking difference between
transgenic lines. Only 1.6% of microglia in SHR transgenic rats expressed MHCII in spite of having a robust
phagocytic phenotype, whereas in WKY transgenic rats, 23.2% of microglia expressed MHCII despite displaying a
considerably lower extent of transformation into phagocytic phenotype.
Conclusions: These results show that the immune response represents a pivotal and genetically variable modifying
factor that is able to influence vulnerability to neurodegeneration. Therefore, targeted immunomodulation could
represent a prospective therapeutic approach to Alzheimer’s disease.
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Alzheimer’s disease (AD) is characterized by progressive
neurodegeneration of the central nervous system. While
the precise aetiology of this disease still remains unknown,
it is believed that the intracellular accumulation of hyper-
phosphorylated tau, which forms neurofibrillary tangles,
and the deposition of extracellular filaments, comprised of
an insoluble form of the b-amyloid protein (Ab), induces
neurodegeneration. From a molecular perspective, AD is a
multifactorial disorder with associations of genetic and
environmental factors [1,2]. The onset and progression of
AD may be influenced by several risk factors such as
hypertension, metabolic disorders like diabetes or
hypercholesterolemia, and inflammatory status [3-5].
Numerous studies on several amyloid mouse models
of Alzheimer’s disease have demonstrated the impor-
tance of genetic background for the expression of the
transgenic phenotype. Significant influences on survi-
val, behaviour, amyloid levels and plaque burden in
brain have been observed [6-10]. Several modifier loci
related to these differences have been identified
[11-13]. Moreover, genetic background-dependent
immunological parameters also modify the effects of
amyloid immunization [14,15]. In contrast to investi-
gated amyloid AD models, the role of genetic back-
ground in tau-induced neurodegeneration has stayed
largely unexplored.
In order to identify the impact of genetic background
on the tau neurodegenerative cascade, we generated a
transgenic rat model expressing human truncated non-
mutated tau protein in the spontaneously hypertensive
rat (SHR) and Wistar-Kyoto (WKY) background. The
SHR strain was chosen because of its propensity for
developing several AD risk factors such as chronic hyper-
tension [16], metabolic syndrome with insulin resistance
[17] and immune alterations [18]. Previously, we showed
that transgenic SHR rats displayed pathological changes
such as the AD-characteristic tau cascade consisting of tau
hyperphosphorylation, formation of sarcosyl-insoluble
tau complexes and neurofibrillary tangles (NFTs) [19]
accompanied with neuroinflammation [20] that resulted in
progressive neurobehavioral impairment [21,22]. The
transgenic phenotype escalates in the terminal stage with
pronounced neurological impairment, hunched posture,
muscular weakness, bradykinesia and paraparesis [21]. For
this comparative study, we used the normotensive Wistar-
Kyoto strain from which the SHR strain was derived. To
maintain the same integration site and number of copies
of the transgene, transgenic SHR rats were back-crossed
to the WKY background.
In this study, we show that misfolded tau proteins
induce neurofibrillary degeneration regardless of back-
ground strain. On the other hand, genetic background
had a significant impact on the pattern of inflammatory
response and the final load of neurofibrillary tangles.
Methods
Animals
SHR 72 transgenic rats (referred to as SHR TG) were
generated to over-express truncated tau protein under
the control of the mouse Thy-1 promoter, as described
previously [19]. The WKY 72 transgenic line (WKY TG)
was developed by back-crossing the SHR 72 line to the
WKY genetic background. This study was performed on
the F5 generation.
Rats were born and bred in our animal facility, and
housed in standard laboratory conditions in plastic
cages (555 × 345 × 195 mm, 5 rats per cage) in a tem-
perature and humidity-controlled environment with a
12/12 hour light/dark cycle and with food and water
available ad libitum. Efforts were made to minimize the
number of animals utilized. All experiments were
performed in accordance to the Slovak and European
Community Guidelines, with the approval of the Insti-
tute’s Ethical Committee and State Veterinary and Food
Administration of the Slovak Republic.
Blood pressure
Systolic blood pressure was measured using indirect tail-
cuff method (LE 5002 Storage pressure meter, BIOSEB)
on the tail arteries of 5 animals of each transgenic and
non-transgenic group at 6 months of age.
Quantitative Western blot analysis
Four-month-old animals, SHR TG males (N = 4) and
WKY TG males (N = 4) were used for quantitative wes-
tern blot analysis. Frozen brain stems of the studied rats
were homogenized in 10 volumes of ice-cold extraction
buffer [in mm: Tris, 20, pH 7.4; NaCl, 150; ethylenediami-
netetraacetic acid (EDTA), 1; dithiothreitol, 1; 0.5% Triton
X-100; Na3VO4,1 ;N a F ,2 0 ;s u p p l e m e n t e dw i t hp r o t e a s e
inhibitors Complete® without EDTA (Roche Diagnostics
GmbH, Mannheim, Germany) using an OMNI TH tissue
homogenizer (OMNI International, Marietta, GA, USA)].
After incubation on ice for 5 min the homogenates were
cleared by centrifugation at 20 000 g for 20 min at 4°C.
The supernatants were collected and the total protein con-
centration was determined using the BioRad protein Assay
(BioRad Laboratories GmbH, Munich, Germany). The
supernatants were then mixed with equal volume of 2 ×
sodium dodecyl sulphate (SDS) sample loading buffer [23]
and heated at 95°C for 5 min. Ten micrograms of
total protein was separated by electrophoresis in 12%
SDS-polyacrylamide gels and then transferred to nitrocel-
lulose membrane in 10 mm N-cyclohexyl-3-aminopropa-
nesulphonic acid (CAPS; pH 12). After the transfer, the
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form transfer of the proteins and then incubated with cell
culture supernatant (1:5) of Hybridoma-producing pan-
tau monoclonal antibody DC25 recognizing residues 347-
354 (Axon Neuroscience, Vienna, Austria), followed by
polyclonal goat anti-mouse IgG, horseradish peroxidase-
conjugated (1:10 000; Dako, Glostrup, Denmark). The
blots were developed using Super- Signal West Pico Che-
miluminescent Substrate (Pierce Biotechnology, Rockford,
IL, USA) and detected with LAS3000 imaging system
(FUJI Photo Film Co., Ltd, Tokyo, Japan). The band inten-
sities were quantified using aida (Advanced Image Data
Analyser software; Raytest, Straubenhardt, Germany).
Gallyas silver staining
To demonstrate the mature neurofibrillary pathology in
neurons, Gallyas silver iodide staining was performed
[24]. Sections were examined with an Olympus BX51
microscope and microphotographs were created with
Olympus camera DP-50.
Frozen sections immunohistochemistry with postfixation
This method was used for the identification of the cell sur-
face markers sensitive to paraformaldehyde fixation. Rats
(5 animals per group, transgenic rats in the terminal stage
of phenotype with age-matched non-transgenic controls)
were deeply anaesthetised with ketamine-xylasine and per-
fused intracardially with phosphate-buffered saline (PBS)
for 2 min using a peristaltic pump. After perfusion, the
brainstem was removed and embedded without fixation in
cryostat embedding medium (Leica) in aluminium foil ves-
sel, and frozen above the surface of liquid nitrogen until
the medium solidified. The sample was left for 1 hour on
dry ice, and then stored at -70°C until used. 10-μm-thick
sections were cut on a cryomicrotome (Leica CM 1850),
affixed onto poly-L-lysine-coated slides, and left to dry at
room temperature for 1 hour. Sections were fixed for 10
min in a 80% acetone:20% ethanol solution. Immunostaining
was performed using the standard avidin-biotin-peroxidase
method (Vectastain ABC kit, Vector Laboratories, USA).
After 20 min in 1% H2O2 and 1 hour blocking in 5%
bovine serum albumin (Sigma), sections were incubated
with primary antibodies OX-42 (CD11b/CD18) and W3/
25 (anti-CD4) (Serotec, UK )o v e r n i g h ta t4 ° C .A f t e r
washing, the sections were incubated 1 hour in biotiny-
lated secondary antibody (Vectastain ABC kit). The reac-
tion product was visualized using avidin-biotin and
Vector VIP as chromogen (Vector).
Frozen section immunohistochemistry with prefixation
This method was used to prepare material for immunohis-
tochemistry of markers tolerant to paraformaldehyde fixa-
tion as ED-1 (anti-CD68, Serotec), DC11 or MN423
(Axon Neuroscience) and for stereological analysis. Rats
were deeply anaesthetised with ketamine-xylasine and
perfused intracardially using a peristaltic pump: for 1 min
with phosphate-buffered saline (PBS) and for 7 min with
4% paraformaldehyde in PBS, pH 7.2 (4% PFA). The brain
was post-fixed overnight in 4% PFA, cryoprotected with
15% and 25% sucrose solutions (subsequently overnight),
frozen in 2-methylbutane (30 seconds at -42°C) and trans-
ferred to dry ice. Sagittal brainstem sections (40 μm thick)
were cut on a Leica CM1850 cryomicrotome.
For stereological analysis, every 13th section was
included in the series (section sampling fraction = 1/13,
total 17-19 sections per animal). Tissue sections were
incubated with primary antibodies AT8 (Pierce Endo-
gen), OX-6 (anti-MHCII, Serotec), anti-Iba1 (WAKO,
USA), anti-NeuN antibody (Chemicon, USA) or anti-
GFAP (Dako, Belgium) overnight at 4°C. Sections were
immunostained using the standard avidin-biotin-peroxidase
method (Vectastain ABC kit) with VIP as chromogen and
5 minute counterstaining of cell nuclei by methyl green
(Vector).
Stereological quantification
For stereological quantification, male rats of transgenic
lines SHR TG (N = 5) and WKY TG (N = 5), in the term-
inal stage of transgenic phenotype development, were
used along with their non-transgenic littermates as age-
matched controls (SHR crl, N = 4 and WKY crl, N = 6).
The numbers of Iba1-positive microglia, MHCII-positive
microglia, neurofibrillary tangles, neurons and astrocytes
were quantified by stereology in brainstem (pons and
medulla oblongata). This region of interest was chosen
because it is highly affected by the neurofibrillary pathol-
ogy in the brain of these tau transgenic rats.
The study was accomplished using an optical fractiona-
tor approach on a modified light microscope (Olympus
BX51) equipped with a computer-based stereological
system (StereoInvestigator; MicroBrightField, Williston,
VT, USA). The region of interest was selected at low
magnification (objective 4 × UPlanFI), and counting was
performed at high magnification using an objective with
a high numerical aperture (60 × oil immersion objective,
Olympus, UPlanFI, NA = 1.25) and oil condenser (Olym-
pus, UAAC, PlanApo, NA = 1.40). Parameters of the
stereological analysis (disector base, sampling grid) were
chosen according to density of the particular structure
(e.g. NFT, microglia) in the tissue - sparse NFTs required
a denser grid than did frequent microglia to ensure pre-
cise analysis with appropriately low coefficient of error.
Detailed parameters of the stereological analysis are
described in Table 1.
Statistical analysis
All data sets are expressed as mean ± standard error
of the mean (SEM). Results were examined using an
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case of uneven variances) and two-way ANOVA using
Prism GraphPad Software Version 4.03 (Graph Pad Soft-
ware, Inc., USA). Differences were considered to be
statistically significant if p < 0.05.
Results
Back-crossed WKY TG rats remain normotensive and
maintain WKY habitus
The SHR TG line was back-crossed to the WKY genetic
background. WKY TG rats in the F5 generation showed
typical WKY habitus (Figure 1A, C) characterized by
elongated skull shape and increased body size and body
weight compared to SHR rats (Figure 1B, D). At 24
weeks, the mean body weight was 425 g ± 18 in WKY
TG rats, 501 g ± 14 in WKY controls, 295 g ± 8 in SHR
TG rats and 337 g ± 7 in SHR non-transgenic litter-
mates. While SHR TG and SHR control rats suffered
chronic hypertension, WKY TG remained normotensive
as did WKY control rats (Figure 1E). Transgene expres-
sion, measured as human misfolded tau to rat endogen-
ous tau ratio, was equivalent in both transgenic lines
(Figure 1F) (Student’s t-test with Welch’s correction, t =
0.81, df = 3, p = 0.48).
Neurofibrillary pathology displays similar qualitative but
different quantitative profiles in two transgenic rat
models of tauopathy (SHR and WKY)
Argyrophilic neurofibrillary tangles (NFTs) and axonal
degeneration were prominent in the brainstem and
spinal cord of transgenic SHR and WKY rats. Neurofi-
brillary pathology was detected by Gallyas silver staining
(Figure 2A, B) and immunolabeled with monoclonal
antibody AT8 that recognizes tau protein phosphory-
lated at Ser202 and Thr205 (Figure 2C-F). Immunos-
taining with antibodies that label conformationally
modified tau (DC11, MN423) did not reveal significant
differences between transgenic rat lines (data not
shown). Despite similar transgene expression levels in
the brainstems of both lines, stereological analysis of
terminal-staged transgenic rats revealed a significantly
lower number of AT8-positive NFTs in the brainstem of
W K YT Gl i n et h a ni nS H RT G( S t u d e n t ’st - t e s t ,t=
2.67, df = 8, p < 0.05) (Figure 2G, H). The difference
was approximately 1,6-fold.
Genetic background determines neuroinflammatory
pattern in transgenic rats
In brain areas harbouring neurofibrillary pathology and
axonopathy, extensive inflammation mediated by reac-
tive microglia was observed. In both transgenic lines,
immunohistochemical staining showed activated mor-
phology of microglia (thick shortened processes, macro-
phage-like morphology, forming of cell clusters) and
increased microglial expression of activation markers:
CD4, CD11b/CD18 and CD68 (Figure 3). Stereological
quantification of cells stained by the general microglial
marker Iba1 was performed in both transgenic lines and
age-matched controls (Figure 4). The terminal stage of
the transgenic phenotype was characterized by a two-
fold increase in Iba1-positive microglia compared to
control WKY or SHR rats (Figure 4G). Two way
ANOVA showed that the transgenic factor creates
approximately 74.5% of variability in microglial counts
(F = 73.08, p < 0.0001), while the factor of genetic back-
ground demonstrates only a non-significant trend
towards increased number of Iba1-positive microglia in
SHR TG rats and control rats compared to WKY TG
and WKY controls (F = 4.198, p = 0.057). The results
were not significantly influenced by the interaction of
examined factors (F = 2.06, p = 0.17). In the stereologi-
cal quantification of the Iba1-positive cells, phagocytic
morphology (Figure 4E, F - highlighted by arrows) was
likewise considered. Macrophage-like structures were
frequently observed in transgenic brainstems, but occa-
sionally seen in control rats. The average ratio of phago-
cytic morphology observed among Iba1-positive cells
was 8.9% in WKY TG rats, 14.5% in SHR TG, 0.8% in
Table 1 Parameters of the stereological analysis
dissector sampling
base height Grid UGZ BA t
Structure quantified (antibody) OBJ ssf (μm×μm) (μm) (μm×μm) (μm) (μm) (μm) ∑OD ∑Q- CE
Neurofibrillar tangles (AT8) 60 × 1/13 100 × 100 15 370 × 370 1.5 40 21.85 3296.70 394.80 0.060
Microglia (Iba1) 60 × 1/13 70 × 70 15 860 × 860 1.5 40 24.41 767.20 1115.40 0.030
Macrophage-like structures (Iba1) 60 × 1/13 70 × 70 15 860 × 860 1.5 40 24.41 767.20 96.00 0.260
MHCII-positive microglia - frequent (MHCII) 60 × 1/13 100 × 100 15 500 × 500 1.5 40 25.60 2645.40 1861.40 0.041
MHCII-positive microglia - sparse (MHCII) 60 × 1/13 100 × 100 15 370 × 370 1.5 40 26.54 4029.20 252.20 0.085
Astrocytes (GFAP) 60 × 1/13 70 × 70 15 860 × 860 1.5 40 24.66 680.19 1696.05 0.024
Neurons (NeuN) 60 × 1/13 70 × 70 15 650 × 650 1.5 40 20.70 1243.76 1655.81 0.047
Abbreviations: OBJ - objective; ssf - section sampling fraction; UGZ - upper guard zone; BA - block advance (section thickness when cut); t - average number-
weighted section thickness after immunohistochemical processing; ∑OD - average sum of optical dissector used; ∑Q- - average number of markers counted; CE -
coefficient of error (Schmitz-Hof).
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morphology followed a similar but more pronounced
pattern as stereological quantification of the number of
the Iba1-positive microglia, and showed significant dif-
ferences between WKY TG and SHR TG rats (Figure
4H). In two-way ANOVA analysis, the transgenic factor
accounted for 69% of variability in the number of
macrophage-like structures (F = 106.7, p < 0.0001).
However, the factor of genetic background was respon-
sible for 9.85% of the variability (F = 15.13, p = 0.001).
Interaction (F = 12.17, p = 0.003) also influenced the
result significantly, indicating that genetic background
Figure 1 Back-crossed WKY TG rats show the basic features of the WKY strain. Rats of the WKY TG line in the F5 generation demonstrated
morphological features of the WKY strain, including elongated skull shape (A) and increased body size (C), compared to SHR rats (B, D). Systolic
blood pressure measurements show chronic hypertension in SHR controls and SHR TG rats, and confirm normal blood pressure in WKY controls
as well as in the back-crossed WKY TG line (E). The influence of genetic background factor on systolic blood pressure is highly significant (two-
way ANOVA, F = 166.85, *** p < 0.0001), but transgenic factor (F = 1.14, p = 0.30) or their interaction (F = 0.2, p = 0.66) does not influence the
blood pressure of the rats. Transgene expression (measured as ratio of human misfolded to rat endogenous tau) is almost identical in the brains
of SHR TG and WKY TG rats (F).
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Page 5 of 13Figure 2 Qualitative and quantitative profile of neurofibrillary pathology in two transgenic rat models of human tauopathy. NFTs show
similar morphological and immunohistochemical features in both transgenic lines - WKY TG (A, C) and SHR TG (B, D). Neurofibrillary tangles were
stained by Gallyas silver staining (A, B, reticular nuclei) and immunolabeled with antibody AT8 recognizing tau phosphorylated at Ser202 and
Thr205 (C, D, reticular nuclei). Phosphorylated tau is also distributed in neuronal processes, resulting in axonopathy visible in the white matter (E, F).
The number of NFTs was stereologically quantified in brainstem (pons and medulla oblongata) as a region of interest (G). Stereological analysis
revealed significantly lower number of NFTs in WKY TG rats compared to SHR TG rats (H, Student’s t-test, * p < 0.05). Pre-fixed frozen sections. Scale
bars: 50 μm.
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Page 6 of 13Figure 3 Qualitative profile of activated microglia in two transgenic rat models of human tauopathy. Microglia in brainstem of WKY TG
(A, C, E) as well as SHR TG (B, D, F) rats show increased expression of activation markers. Large number of microglia strongly immunoreactive for
CD11b/CD18 (complement 3 receptor) (A, B) demonstrate the involvement of complement system in the tau-induced neuroinflammation. CD4
co-receptor is usually present on T-cells interacting with MHCII-positive antigen presenting cells; in tau-induced neuroinflammation it is increased
mainly on microglia/macrophages (C, D). Round-shaped cell parts positive for CD68 (lysosomal membrane glycoprotein) indicate putative
phagocytosis (E, F). Post-fixed (A, B, C, D) and pre-fixed (E, F) frozen sections. Scale bars: 50 μm.
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Page 7 of 13Figure 4 Qualitative and quantitative profile of activated microglia in two transgenic rat models of human tauopathy.P r o m i n e n t
microgliosis was observed by immunohistochemical staining with Iba1 antibody in both transgenic lines - WKY TG (A) and SHR TG (B) -
compared to non-transgenic WKY (C) and SHR (D) age-matched controls. Stereological quantification revealed that the numbers of Iba1-positive
microglia/macrophages in brainstem of both transgenic lines doubled in comparison with non-transgenic controls (G, two-way ANOVA,
transgenic factor, *** p < 0.0001). There is also a tendency to a higher number of Iba-1 positive microglia in SHR TG rats compared to WKY TG.
The morphology of microglia in brainstem of transgenic rats indicates a high level of activation including presumptive phagocytosis (E, F -
arrows). In SHR TG rats, there are significantly more microglia showing phagocyte-like morphology than in WKY TG (H, two-way ANOVA,
transgenic factor, *** p < 0.0001, genetic background factor, ** p = 0.001). Pre-fixed frozen sections. Scale bars: 50 μm for A-D, 20 μm for E, F.
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phage-like structures in transgenic and control rats.
WKY TG rats express strikingly more MHCII-positive
microglia than SHR TG
Brainstems of transgenic rats were stained for MHC
class II antigens - RT1B (Figure 5.). Quantification of
non-transgenic rats was not undertaken due to lack of
MHCII-positive cells in several control brainstems.
A striking difference in the number of MHCII-immu-
noreactive microglia (Student’s t-test, t = 8.2, df = 8, p <
0.0001) was detected between the genetic backgrounds,
showing different types of microglial activation. In WKY
TG, 23.2% of total (Iba1-positive) brainstem microglia
expressed MHCII, while in SHR TG rats, only 1.6% of
total microglia were MHCII-positive, respectively.
The increase in astrocyte numbers is the same in both
transgenic rat lines regardless of the genetic background
Besides microglial activation, the reaction of astrocytes
was observed and quantified (Figure 6). Independently
from the genetic background, an elevated number of
GFAP-positive astrocytes were counted in both lines of
transgenic rats (SHR TG and WKY TG) in comparison
with non-transgenic age-matched controls. Two-way
ANOVA revealed a significant role of the transgenic fac-
tor impacting 71.53% of variability (F = 71.53, p <
0.0001), while genetic background (F = 0.1, p = 0.80) or
interaction (F = 0.71, p = 0.51) did not influence the
number of GFAP-positive astrocytes.
Discussion
Neurofibrillary degeneration [25,26] and neuroinflamma-
tion [27-29] are prominent features of Alzheimer’sd i s -
ease (AD) and related neurodegenerative disorders.
While neurodegeneration induced by misfolded tau cor-
relates with disease progression [30], inflammation is
considered to be an important factor in the variability in
resistance or susceptibility to AD [5,31]. Polymorphisms
of genes connected to inflammatory pathways are often
among the AD risk factor candidates [32-34]. A recent
transcriptomic study of centenarians has revealed that
immune homeostasis determines cognitive health of the
population aged over 90 years. Genes related to immune
response pathways, particularly antigen presentation,
IL4, natural killer cell signalling, complement pathway
and acute phase signalling are upregulated in cognitively
intact oldest-old (compared to younger adults), while
downregulated in cognitively impaired elderly. Hence,
genes related to immunity and regulation of their
expression significantly influence the pathogenesis of
neurodegeneration [35].
In this study, we have shown that misfolded tau pro-
tein induces neurofibrillary degeneration regardless of
genetic background. However, the immune response dri-
ven by neurodegeneration was significantly determined
by genetic modifiers.
Figure 5 Expression of MHC class II molecules is different in
brains of transgenic rat models. In brainstem of WKY TG rats (A),
activation of microglia is accompanied by widespread MHCII
expression, while in SHR TG (B), only sparse MHCII staining was
recorded. Stereological quantification shows highly significant
differences between the transgenic lines. In WKY TG rats, there are
10 times more microglia that express MHCII than are present in SHR
TG rats (C, Studen’t t-test, *** p < 0.001). Pre-fixed frozen sections.
Scale bars: 50 μm.
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Page 9 of 13Figure 6 Qualitative and quantitative profile of activated astroglia in two transgenic rat models of human tauopathy.T h e r ei sa n
approximately 25% increase in GFAP-positive astrocytes in brainstem in both transgenic lines (A - WKY TG, B - SHR TG) compared to age-
matched controls (C - WKY crl, D - SHR crl). Morphological signs of astrocytic activation and hypertrophy (E) are observed in the brainstems of
both transgenic rat lines. Stereological quantification (F) reveals no significant differences between WKY TG and SHR TG rats in numbers of
GFAP-positive astrocytes. However, the difference in numbers of GFAP-positive astrocytes between transgenic and control rats is highly
significant (two-way ANOVA, transgenic factor *** p < 0.0001). Pre-fixed frozen sections. Scale bars: 50 μm for A-D, 20 μm for E.
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grounds (SHR, Wistar-Kyoto) were utilized expressing the
same amount of human truncated tau. Despite the fact
that the tau expression profile was similar in both trans-
genic lines, the final load of neurofibrillary tangles was sig-
nificantly different. Stereological quantification revealed
lower final NFT load in the brainstem of transgenic WKY
rats compared to transgenic SHR counterparts. Previously,
we showed that the final NFT load in the terminal stage
was independent of transgene expression levels [36]. Alto-
gether, these findings suggest that the final NFT load is
independent of expression levels of misfolded tau protein,
but remains strongly dependent on the interaction of the
transgene and genetic environment.
Neuroinflammation represents one of the key differ-
ences between SHR and Wistar strains. Spontaneously
hypertensive rats (SHR) exhibit chronic neuroinflamma-
tion [37,38]. RT-PCR analysis demonstrates significantly
increased expression of TNFa,I C A M - 1 ,i N O Sa n dt h e
inflammation-related nuclear transcription factor PPARg
in brain in SHR compared to that in WKY rats [39]. In
addition, the brain endothelium of SHR is more sensi-
tive to cytokines; under inflammatory conditions it is
more adhesive to blood monocytes in comparison with
WKY endothelium [40,41]. On the other hand, the
chronic inflammation in SHR rats probably causes an
altered reaction to acute immune challenges. These rats
show an attenuated response to endotoxin shock or
polymicrobial infection, and survive these challenges
better than do WKY rats [42,43]. In order to identify
the impact of neuroinflammation on tau neurodegenera-
tive cascade, we analyzed the pattern of microglial acti-
vation in both transgenic lines (SHR TG and WKY TG).
We discovered that both transgenic rat models demon-
strated the same distribution and immunophenotypic
profile of activated microglia. Despite profound similari-
ties between both transgenic lines, several features of
neuroinflammation revealed striking differences that
were driven by their genetic background (Table 2.).
Transgenic SHR rats displayed increased number of
microglia and significantly more Iba1-positive cells with
phagocytic morphology than WKY transgenic rats. In
h u m a nA Db r a i n ,A b-phagocytosing cells operate effi-
ciently in healthy brain, but are inefficient in AD
patients. These Ab-phagocytosing cells appear to be
mainly blood-borne macrophages [44,45]. Similarly, we
have shown that at least some of the cells with phagocy-
tic morphology in our model comprise macrophages
infiltrating from the blood [20], suggesting that macro-
phages may play important role in the immune response
in the transgenic rats expressing truncated tau.
The most profound difference was found in the
number of MHC class II positive microglial cells. In
WKY transgenic rats, 23.2% of Iba1-positive microglia
were MHCII-positive, while in transgenic SHR rats,
only 1.6% of microglia expressed MHCII. Microglial
expression of MHCII is considered to be a response to
phagocytosis of tissue debris, involved in activating
antigen cleavage machinery [46]. However, in our
model, SHR transgenic rats showed a higher number
of cells with phagocytic morphology but only a sparse
MHCII signal. A similar discrepancy between MHCII
expression and markers of phagocytosis has been
described for a model of spinal cord injury. These
authors demonstrated that Lewis rats exhibit more
antigens related to complement and phagocytosis,
while Sprague Dawley rats express more MHCII anti-
gens [47]. We suppose that the tendency to increased
microglial numbers and significantly more phagocytic
morphology in SHR microglia may be a compensatory
reaction for the inability to amplify MHCII expression.
The functional impact of microglial MHCII expression
on neurodegeneration is not yet fully understood. Mod-
els of CNS injury reveal that extensive MHCII expres-
sion correlates with tissue damage. In a ventral root
avulsion model [48], MHCII expression accompanies
increased motoneuron loss. Furthermore, rat strains
with higher MHCII expression are also more susceptible
to experimental autoimmune encephalomyelitis. Simi-
larly, Kigerl et al. [49] reported impaired recovery and
more extensive lesion volume in mouse strain with the
highest levels of MHCII in a model of spinal cord injury.
In our study, WKY TG rats, displaying increased num-
bers of MHCII positive microglia, showed higher vulner-
ability to tau-induced neurodegeneration compared to
SHR TG rats: lower burdens of neurofibrillary pathology
sufficed for WKY TG rats to reach the terminal stage of
transgenic phenotype. These results suggest that micro-
glia expressing MHCII can considerably modify the pro-
gression of neurodegeneration. This hypothesis should
be validated by further experiments including assess-
ment of functional behavioural changes and morality.
Table 2 Pattern of the tissue response
AT8-positive Iba1-positive Iba1-positive MHCII-positive GFAP-positive
NFTs microglia phagocytes microglia astrocytes
WKY TG ++ ++(+) ++ +++ ++
SHR TG +++ +++ +++ + ++
Pattern of the tissue response on the tau-induced neurodegeneration in the terminal stage of transgenic phenotype, revealed by stereological quantification.
Stozicka et al. Journal of Neuroinflammation 2010, 7:64
http://www.jneuroinflammation.com/content/7/1/64
Page 11 of 13Besides microglial activation, we also observed
increased numbers of activated hypertrophic astrocytes
in both transgenic rat lines. Astrogliosis - astrocytic acti-
vation associated with inflammatory signaling and
decrease in trophic support of neurons - is a common
feature of neurodegenerative conditions, including
human AD and transgenic models with amyloid or tau
pathology [50-58]. Surprisingly, in our experimental
conditions, the increase in number of GFAP-positive
astrocytes was not influenced by genetic background.
However, we cannot exclude that the genetic environ-
ment could modify the functional properties of activated
astrocytes.
Conclusions
In this report, we have shown for the first time that
genetic background has a strong influence on the load
of neurofibrillary tangles and the inflammatory pattern
of activated microglia. These findings suggest that brain
immune response is a potent disease modifier of neuro-
fibrillary degeneration. We therefore conclude that tar-
geted immunomodulation rather than anti-inflammatory
strategies may represent a prospective therapeutic ave-
nue for Alzheimer’s disease.
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